Washington University School of Medicine Digital Commons@Becker

Presentations

2005: Alcoholism and Comorbidity

2005

Schizophrenia and alcoholism

Kim Mueser Dartmouth Medical School

Follow this and additional works at: http://digitalcommons.wustl.edu/guzepresentation2005 Part of the <u>Medicine and Health Sciences Commons</u>

Recommended Citation

Mueser, Kim, "Schizophrenia and alcoholism" (2005). *Presentations*. Paper 5 Samuel B. Guze Symposium on Alcoholism. http://digitalcommons.wustl.edu/guzepresentation2005/5

This Presentation is brought to you for free and open access by the 2005: Alcoholism and Comorbidity at Digital Commons@Becker. It has been accepted for inclusion in Presentations by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Schizophrenia and Alcoholism

Kim Mueser, Ph.D.

Dartmouth Medical School NH-Dartmouth Psychiatric Research Center

Kim.t.mueser@dartmouth.edu

Overview

- Prevalence of alcoholism in schizophrenia
- Correlates and consequences of alcoholism in schizophrenia
- Models explaining excessive comorbidity
- Integrated treatment




Table of Contents

I. Basics

- 1. Substance Abuse and Severe Mental Illness
- 2. Principles of Integrated Treatment
- 3. Basic Organizational Factors
- **II.** Assessment and Treatment Planning
 - 4. Assessment I: Detection, Classification, and Functional Assessment
 - 5. Assessment II: Functional Analysis and Treatment Planning

III. Individual Approaches

- 6. Stage-Wise Case Management
- 7. Motivational Interviewing
- 8. Cognitive-Behavioral Counseling
- IV. Group Interventions
 - 9. Persuasion Groups
 - 10. Active Treatment Groups
 - 11. Social Skills Training
 - 12. Self-Help Groups

- V. Working with Families
 - 13. Family Collaboration
 - 14. Behavioral Family Therapy
 - 15. Multiple-Family Groups
- VI. Other Treatment Approaches
 - 16. Residential Programs
 - 17. Coerced and Involuntary Interventions
 - 18. Vocational Rehabilitation
 - 19. Psychopharmacology

- V. Working with Families
 - 13. Family Collaboration
 - 14. Behavioral Family Therapy
 - 15. Multiple-Family Groups
- VI. Other Treatment Approaches
 - 16. Residential Programs
 - 17. Coerced and Involuntary Interventions
 - 18. Vocational Rehabilitation
 - 19. Psychopharmacology


VII. Research

20. Research on Integrated Dual Disorder Treatment


Epilogue Avoiding Burnout and Demoralization Prevalence (%) of Lifetime Substance Use Disorder for Various Psychiatric Disorders

- Any Substance Use Disorder
- Any Alcohol Use Disorder
- Any Drug Use Disorder
- *Data From ECA Study


Any Substance Use Disorder




Any Alcohol Use Disorder



Any Drug Use Disorder



Rates of Lifetime Substance Use Disorder (SUD) among Recently Admitted Psychiatric Inpatients (N=325) (Mueser et al., 2000)



Factors Influencing Prevalence of Substance Use Disorders (SUD): Client Characteristics

Higher Rates

- Males
- Younger
- Lower education
- Single or never married
- Good premorbid functioning

- History of childhood conduct disorder
- Antisocial personality disorder
- Higher affective symptoms
- Family history SUD

Clinical Epidemiology

- 1. Rates higher for people in treatment
- 2. Approximately 50% lifetime, 25%35% current substance abuse
- Rates are higher in acute care, shelter, institutional, and emergency settings
- 4. In most settings, alcohol is most commonly abused substance

Common Consequences of Substance Abuse in Schizophrenia


- Relapse and rehospitalization
- Financial problems
- Family burden
- Housing instability and homelessness
- Non-compliance with treatment

- Violence
- Suicide
- Legal problems
- Prostitution
- Health problems
- Infectious disease risky behaviors

Models of Comorbidity: Berkson's Fallacy

Rates of comorbidity for any two disorders tend to be higher in clinical samples (vs. general population samples) and in treatment settings (than non-treatment settings) because either disorder is likely to propel the person into treatment.

Models of Comorbidity



Secondary Mental Illness Models: Schizophrenia

- Chronic stimulant use as precipitant of schizophrenia: lack of replication of early findings
- Hallucinogen abuse as precipitant of long-term psychosis: clients tend to have relatives with psychosis
- Cannabis prospectively predicts onset of schizophrenia: 1) can't explain stable rate of schizophrenia following rise in cannabis use; 2) may be accounted for by early prodrome involving mood disturbance

Secondary Substance Abuse Models

- Self-medication
- General dysphoria
- Super-sensitivity
- Secondary psychosocial effects

Self-Medication Hypothesis

- Substance type unrelated to specific symptoms of schizophrenia
- Symptom severity unrelated to substance abuse
- Clients usually don't report substances
 reduce symptoms


General Dysphoria Hypothesis

- Dysphoria common in schizophrenia, usually precedes onset of psychosis and persists throughout illness
- Some evidence linking trait dysphoria to substance abuse in schizophrenia
- Inconsistent findings suggesting link between depression and substance abuse in schizophrenia


Super-sensitivity Model

- Biological sensitivity increases vulnerability to effects of substances in schizophrenia
- Smaller amounts of substances result in problems
- "Normal" substance use is problematic for clients with schizophrenia but not in general population
- Sensitivity to alcohol and other substances, rather than high amounts of use, makes many clients with schizophrenia different from general population

Stress-Vulnerability Model



Status of Moderate Drinkers with Schizophrenia 4 - 7 Years Later (N=45)



Source: Drake & Wallach (1993)

Support for Super-sensitivity Model

- People with schizophrenia less likely to develop physical dependence on substances
- Standard measures of substance abuse are less sensitive in clients with schizophrenia
- Clients are more sensitive to effects of small amounts of substances
- Few clients are able to sustain "moderate" use without impairment
- Super-sensitivity accounts for some increased comorbidity

Secondary Psychosocial Effects Model

- Psychosocial consequences of schizophrenia increase vulnerability to substance abuse (limited research):
 - Cognitive impairment
 - Social extrusion
 - Poverty
 - Increased sensitivity to stress
 - Free time/no work, parenting responsibilities

Common Factor Models

- Genetic vulnerability (not supported)
- Cognitive impairment (limited data)
- Social disadvantages (limited data)
- ASPD

Antisocial Personality Disorder (ASPD)


Research


- Conduct Disorder (CD) and ASPD have high comorbidity with substance abuse
- CD often precedes onset of schizophrenia
- ASPD has high comorbidity with schizophrenia
- CD and ASPD have a high comorbidity with SUD in clients with schizophrenia
- Among dually diagnosed patients, CD and ASPD are associated with more severe SUD


Conclusion

• ASPD is a common factor that may account for some increased comorbidity between schizophrenia and substance abuse

CD, ASPD, and Recurrent Substance Abuse Disorders









Source: Mueser, et. al. (1999)

Summary of Models of Comorbidity

- Secondary mental illness: limited support, but drug abuse may precipitate earlier age onset of schizophrenia in some vulnerable cases
- Secondary substance abuse: support for supersensitivity model; marginal support for dysphoria hypothesis
- Common factors: support for ASPD

Treatment Barriers

- Historical division of service and training
- Sequential and parallel treatments
- Organizational and categorical funding barriers in the public sector
- Eligibility limits, benefit limits, and payment limits in the private sector

Integrated Treatment

- Mental health and substance abuse treatment
 - Use Delivered concurrently
 - Use By the same team or group of clinicians
 - Within the same program
 - The burden of integration is on the clinicians

Other Features of Dual Disorder Programs

- Assertive outreach
- Long-term commitment
- Comprehensive treatment
- Reduction of negative consequences
- Stage-wise treatment: engagement, persuasion, active treatment, and relapse prevention

What are the Stages of Treatment?

 Engagement, persuasion, active treatment, and relapse prevention

- 2. Not linear
- 3. Stage determines goals
- 4. Goals determine interventions
- 5. Multiple options at each stage

What Do We Do During Engagement?

- <u>Goal</u>: To establish a working alliance with the client
- <u>Clinical Strategies</u>
 - 1. Outreach
 - 2. Practical assistance
 - 3. Crisis intervention
 - 4. Social network support
 - 5. Legal constraints

What Do We Do During Persuasion?

- <u>Goal</u>: To motivate the client to address substance abuse as a problem
- <u>Clinical Strategies</u>
 - 1. Psychiatric stabilization
 - 2. "Persuasion" groups
 - 3. Family psychoeducation
 - 4. Rehabilitation
 - 5. Structured activity
 - 6. Education
 - 7. Motivational interviewing

What Do We Do During Active Treatment?

• <u>Goal:</u>

To reduce client's use/abuse of substance

<u>Clinical Strategies</u>

- 1. Self-monitoring
- 2. Social skills training
- 3. Social network interventions
- 4. Self-help groups

- **5.** Substitute activities
- 6. Close monitoring
- 7. Cognitive-behavioral techniques to address:
 - High risk situations
 - ↓Craving
 - Motives for substance use
 - **↓**Socialization
 - Persistent symptoms
 - ↓Pleasure enhancement

What Do We Do During Relapse Prevention?

• <u>Goals:</u>

- To maintain awareness of vulnerability and expand recovery to other areas
- <u>Clinical Strategies</u>
 - 1. Self-help groups
 - 2. Cognitive-behavioral and supportive interventions to enhance functioning in:
 - Work, relationships, leisure activities, health, and quality of life

Relapse Prevention Strategies

- Construction a relapse prevention plan:
 - Risky situations
 - Early warning signs
 - Immediate response
 - Social supports
 - Abstinence violation effect

Research on Integrated Treatment (IT)

- 26+ RCT or quasi-experimental studies of IT (reviewed by Drake et al., 2004)
- 3/4 studies of brief motivational interviewing interventions showed positive effects
- 6/7 studies found group intervention better than 12step or standard care

Research on IT (Cont.)


- Family intervention: no RCTs examining family treatment alone
- Comprehensive IT: 2 RCT & 1 quasiexp. study favor comp. IT over treatment as usual
- Intensity: more intensive IT produces slightly better outcomes (e.g., Drake et al., 1998)

Drake et al. (1998)

- 203 clients (77% schizophrenia)
- ACT vs. standard case management (SCM) (both IT)
- 3 year follow-up
- ACT better than SCM in alcohol severity & stage of treatment
- No differences in hospitalization, symptoms, quality of life


NH Dual Diagnosis Study

Proportion of Days in Stable Community Housing




- 1. Proportion of days in stable community housing (regular apartment or house, not in hospital, jail, homeless setting or doubling with friends or family) increased for all dual diagnosis clients.
- 2. They increased more rapidly for persons in recovery (no substance abuse for at least 6 months).

NH Dual Diagnosis Study



- 1. Percentage of persons hospitalized during each six months declined significantly for all clients.
 - 2. It declined much more for those in recovery.

Fidelity to IT Model Improves Outcome



Limitations of Research

- Lack of standardization of treatments
- No or limited fidelity assessment
- No replication of program effects
- Unclear or variable comparison conditions

Conclusions

- Substance use disorders are common in schizophrenia and contribute to worse outcomes
- Increased comorbidity is due partly to high sensitivity to effects of substances, and ASPD operating as a common factor increasing risk of each disorder
- Integrated treatment models treat both disorders concurrently, & employ motivation-based, comprehensive interventions
- Early research on integrated treatment provides evidence supporting its effects on improve substance abuse